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Voltage-dependentInvestigation of the mechanistic bases and physiological importance of cAMP regulation of HCN channels has
exploited an arginine to glutamate mutation in the nucleotide-binding fold, an approach critically dependent
on the mutation selectively lowering the channel's nucleotide afﬁnity. In apparent conﬂict with this, in intact
Xenopus oocytes, HCN and HCN-RE channels exhibit qualitatively and quantitatively distinct responses to the
tyrosine kinase inhibitor, genistein — the estrogenic isoﬂavonoid strongly depolarizes the activation mid-
point of HCN1-R538E, but not HCN1 channels (+9.8 mV±0.9 versus +2.2 mV±0.6) and hyperpolarizes
gating of HCN2 (−4.8 mV±1.0) but depolarizes gating of HCN2-R591E (+13.2 mV±2.1). However, excised
patch recording, X-ray crystallography and modeling reveal that this is not due to either a fundamental effect
of the mutation on channel gating per se or of genistein acting as a mutation-sensitive partial agonist at the
cAMP site. Rather, we ﬁnd that genistein equivalently moves both HCN and HCN-RE channels closer to the
open state (rendering the channels inherently easier to open but at a cost of decreasing the coupling energy
of cAMP) and that the anomaly reﬂects a balance of these energetic effects with the isoform-speciﬁc
inhibition of activation by the nucleotide gating ring and relief of this by endogenous cAMP. These ﬁndings
have speciﬁc implications with regard to ﬁndings based on HCN-RE channels and kinase antagonists and
general implications with respect to interpretation of drug effects in mutant channel backgrounds.© 2009 Elsevier B.V. All rights reserved.Introduction
cAMP facilitates opening of cyclic nucleotide gated (CNG) and
hyperpolarization-activated cyclic nucleotide-regulated (HCN) pace-
maker ion channels by binding to, and regulating the conformation of,
a cyclic nucleotide gating ring formed from a binding domain (the
CNBD) and a short linker (the C-linker) that physically links the CNBD
to the S6 activation gate [1,2]. Recently, considerable insight has been
obtained into the mechanism and stoichiometry by which the gatinglogy, Eye Institute Research
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hysics, University of California
usetts Institute of Technology,
ll rights reserved.ring regulates HCN voltage-dependent activation [3–15]. While the
nature of the transitions undergone by the gating ring (such as
whether it involves a switch from a four-fold to a two-fold symmetric
“dimer of dimers” arrangement [6–9]) and the extent of coupling of
motions of the CNBD and C-linker have yet to be fully resolved
[2,8,11,16], the ﬁndings are in general agreement with a model
wherein the unoccupied, deactivated gating ring stabilizes the closed
channel [2–4,8,11,17]. In this framework, tighter agonist binding to the
activated gating ring promotes channel opening because it overcomes
the basal inhibitory effect of the deactivated gating ring [2–4,8,11,16].
A further reﬁnement of this model indicates that, in addition to
stabilizing the open channel relative to the closed channel, cAMP
occupancy of the CNBD decreases the occupancy of a “voltage-
desensitized” conformation [10].
Importantly, aspects of this model have been obtained through
analysis of mutants that render the gating ring insensitive to
physiological levels of cAMP by mutation of a critical arginine (see
Fig. 6A) that interacts with the cyclized phosphate of the ligand
[5,6,9,14,18]. Moreover, using a “knock-in” approach, this mutation has
been introduced into mice to probe the physiological role of cAMP
regulation of HCN channels [19]. A critical assumption in such
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without perturbing the fundamental energetics of the voltage sensors
or of the activation gate. Previous studies have appeared to validate
this assumption and, additionally, suggested that the arginine-
nucleotide interaction contributes only to the initial binding energy
that serves to dock cAMP in the pocket and not to coupling energy
[2,7,18,20].
Several studies considering a potential role for tyrosine kinases as
regulators of HCN channels have shown that channel function is
altered by the estrogenic isoﬂavonoid tyrosine kinase inhibitor,
genistein, although there has been considerable disagreement as to
whether the ligand acts via disruption of tyrosine phosphorylation
[21–23] or through tyrosine phosphorylation independent mechan-
isms [24,25]. While analyzing the sensitivity of HCN channel gating to
such steroid like molecules we observed that, in two electrode voltage
clamp (TEVC) recordings from intact Xenopus oocytes, HCN-RE
channels responded very differently to genistein when compared to
their cognate wild type counterparts. These observations raised the
possibility that genistein was serving as a detector of abnormal
aspects of gating within these mutants, a ﬁnding that could call into
question aspects of the cAMP-gating model that are dependent on
interpretation of the responses of the HCN-RE constructs and would
raise questionswith regard to the interpretation of HCN-RE “knock-in”
mice. Moreover, the ﬁnding suggested the confusion among studies
using kinase inhibitors might have an intriguing origin.
By use of excised inside-out patch clamp recording (IOPC) and X-
ray crystallography, combined with interpretation within a simple
cyclic gating scheme, we ﬁnd that the apparent RE-sensitivity of
genistein's actions arises from a synthesis of three inﬂuences: 1. The
strength of the HCN isoform-dependent basal inhibition of activation
by the cAMP-vacant gating ring; 2. The efﬁcacy with which this is
overcome upon cAMP occupancy of the CNBD at physiological
concentrations of the agonist and 3. A phytoestrogen-mediated
movement of the channels towards their open state, a change that
elicits a corresponding decrease in the coupling energy available from
bound cAMP. Thus, as HCN-RE channels are uncoupled from
physiological levels of cAMP (and so are fully inhibited by their gating
ring) their activation is enhanced by genistein in intact oocytes. In
contrast, for wild type channels, the loss of favorable coupling to basal
cAMP in intact oocytes offsets the genistein-mediated enhancement
of opening such that genistein elicits a weaker facilitation (HCN1) or
an overall inhibition of gating (HCN2).
With respect to understanding the function and physiology of HCN
channels, our analysis provides a novel demonstration that RE mutant
HCN channels behave faithfully as cAMP-decoupled channels, shed
light on the conﬂicting studies addressing the role of tyrosine kinases
as regulators of HCN function and suggest that endogenous steroidal
compounds may act as novel, cAMP sensitive, regulators of HCN
channel function. In a broader context, our ﬁndings serve to illuminate
how mechanistic interpretation of a residues' role in a particular
function can be subject to gross misinterpretation.
Materials and methods
Molecular biology and protein preparation
For functional studies, murine HCN1 and HCN2 channels (and
mutants thereof) were subcloned into pGH19 and pGHE expression
vectors, respectively. HCN-RE channels and CNBD truncation con-
structs were made by site-directed PCR mutagenesis as described
previously [3,18]. The sequences of all clones were conﬁrmed by
sequencing PCR ampliﬁed fragments on both strands. Residues are
numbered according to the full-length channel sequences. Constructs
were ampliﬁed in STBL2 cells (Invitrogen Corporation, Carlsbad, CA).
cRNA was transcribed from NheI (HCN1 constructs) or SphI (HCN2
constructs) linearized DNA using T7 RNA polymerase (MessageMachine; Ambion, Houston, Tx). 1–50 ng RNA was injected into
each Xenopus oocyte.
For crystallization studies, we followed the protocol as previously
described by Zagotta et al. [7]. Brieﬂy, a DNA fragment encoding
residues 443–640 of the murine HCN2 channel was expressed with
the pETGQ vector in Escherichia coli (construct HCN2I). Cells
expressing HCN2I were harvested by centrifugation and lysed in a
HEPES based buffer at 4 °C. The construct was isolated by Ni-NTA
chromatography and the octahistidine tag was removed by thrombin
cleavage. The tag-less construct was puriﬁed using cation exchange
followed by size exclusion chromatography. Pooled fractions were
dialyzed against a modiﬁed HEPES buffer and concentrated to 5–
7 mg/mL prior to crystallization.
Electrophysiology
Recordings were made in either TEVC or IOPC conﬁgurations from
Xenopus oocytes 1–5 days after cRNA injection. Cells were maintained
in L-15mediawithout ﬁcoll (SpecialtyMedia, Phillipsburg, NJ) at 17 °C
until use. In both conﬁgurations, data were digitized using an ITC-18
interface (Instrutech Corporation, Port Washington, NY) and recorded
with Pulse software (HEKA Elektronik, Lambrecht/Pfalz, Germany).
Ag–AgCl ground wire(s) were connected to the bath solution by 3 M
KCl–2% agar salt bridges placed downstream of, but close to, the
oocyte. Recordings were obtained at room temperature (22–25 °C). In
all cases voltages are reported as the command potentials. In TEVC the
measured deviation was less than 1%.
TEVC data were acquired using a Warner Instruments (Hamden,
CT) OC-725C ampliﬁer, ﬁltered at 1 kHz then digitized at 2 kHz.
Oocytes were bathed in a recording solution of (in mM) 107 NaCl, 5
KCl, 2 MgCl2, and 10 HEPES-free acid pH 7.4 (NaOH). Microelectrodes
were fabricated from 1B120-F4 borosilicate glass (World Precision
Instruments, Sarasota, FL) and had resistances of 0.1–0.5 MΩ (I
passing) and 1–4 MΩ (V sensing) when ﬁlled with 3 M KCl. An active
virtual ground was used to clamp the bath.
IOPC data were acquired using an Axon Instruments 200B patch
clamp ampliﬁer (Axon Instruments, Foster City, CA) in resistive mode
and then digitized at 5 kHz followingﬁltering at 2.5 kHz (Warner LPF-8
8-pole Bessel ﬁlter). The extracellular solutionwas (in mM) 107 KCl, 5
NaCl, 1 MgCl2, 1 CaCl2, and 10 HEPES-free acid pH 7.4 (KOH). The
intracellular solutionwas (inmM)107KCl, 5NaCl,1MgCl2,1 EGTA-free
acid, and 10HEPES-free acid pH 7.4 (KOH). cAMPwas applied as the Na
salt. In experiments where we applied 50 mM cAMP, the bath solution
was adjusted so that the NaCl and KCl concentrations in the absence of
cAMP were 50 and 62 mM and the Na cAMP was substituted for NaCl.
Electrodes with resistances between 1 and 2MΩwere fabricated from
Kimax-51 borosilicate glass (Kimble Glass, Vineland, NJ) and coated
with sylgard (Dow Corning Corporation, Midland, MI). In patches
where the maximal current exceeded 500 pA, we applied analogue
series resistance compensation (90% correction, 20 μs lag with the
resistance set to the initial resistance of the electrode). HCN channel
gating spontaneously shifts hyperpolarized following patch excision.
Accordingly, data acquisition was not begun until 3 min after patch
excision into the Mg containing solution, a time sufﬁcient to permit
activation to largely equilibrate to the cell free level.
Paradigms and analysis
Steady-state activation curves were determined from tail currents
(measured at 0 mV in TEVC and −40 mV in IOPC) following
hyperpolarizing voltage steps applied in −10 mV increments. The
holding potential was −40 mV in IOPC and −30 mV in TEVC. Tail
current amplitudes were measured by averaging the current during
the plateau of the tail (after allowing the voltage clamp to settle and
the uncompensated linear capacitance and Mg block [26,27] to decay)
and subtracting from this the baseline current recorded after the
1941A.O. Rozario et al. / Biochimica et Biophysica Acta 1788 (2009) 1939–1949channels had fully deactivated. Tail current amplitudes were plotted
versus the hyperpolarizing step voltage and ﬁtted with the Boltzmann
equation (Eq. (1)).
I Vð Þ = A1 + A2 = 1 + exp V − V1=2
 
= s
h in o
ð1Þ
Here A1 is the current offset, A2 is themaximal current amplitude, V
is the step voltage, V1/2 is the activation mid-point voltage and s is the
slope factor deﬁned as RT/zFwhere z is ameasure of the gating charge
associated with channel activation and opening and R, T and F have
their usual meaning. The tail amplitudes and Boltzmann ﬁt were then
normalized to the maximal tail amplitude according to [I(V) – A1] / A2.
To follow changes in activation with greater temporal resolution
than can be achieved when constructing full activation curves
(channel gating is extremely slow), we adopted a protocol that
would determine an approximate measure of the change in the V1/2.
Each 30 or 60 s, a cell or patch was stepped to an intermediate voltage
(VINT) that would achieve ∼50% activation (determined from a full
activation curve constructed at the beginning of the recording).
Following determination of the intermediate current (IINT), the
corresponding tail current (IINT TAIL) and a sojourn at the holding
potential, the cell/patch was stepped to a voltage that saturated
channel opening (VMAX), and the maximal current (IMAX) and
corresponding tail current (IMAX TAIL) were determined. From these
data we constructed conductance ratios: GINT TAIL/GMAX TAIL and GINT/
GMAX by correcting current ratios for driving force using determined
values of the reversal potential. These non-linear gating parameters
(GR in Eq. (2)) were then converted into linear approximations of the
shift in the V1/2, the “ΔV1/2 apparent” (ΔV1/2 APP) using Eq. (2).
ΔV1=2 APP = − s Ln 1− GR½ = GR exp VINT = sð Þ− exp VMAX = sð Þ
h in o
− V1=2
ð2Þ
Here, V1/2 and s are activation mid-point and slope determined
from a ﬁt of the Boltzmann Eq. (1) to an initial steady-state activation
curve (see [28] for further details). Analysis of GINT TAIL/GMAX TAIL or
GINT/GMAX yielded equivalent estimations of ΔV1/2 APP.
Crystallization and structure determination
Crystals of HCN2I in the presence of cAMP were generated by the
hanging drop method as previously described [7]. Crystals were bi-
pyramidal in shape and belong to the space group I4. Attempts to
incorporate genistein into the crystals were conducted by soaking
harvested crystals in solutions containing genistein. Working from a
100mMstock of genistein in DMSO, three solutions of 4mM, 8mM, and
20mMgenisteinweremadewith protein crystallization buffer (20mM
HEPES,150mMNaCl,1mMdithiothreitol, 5mMcAMP, pH7).Harvested
crystals were sequentially soaked for 1 min in solutions of increasing
genistein concentration made by mixing 5 μL of diluted genistein with
5 μL of mother liquor. Crystals were cryoprotected in the ﬁnal soak solu-
tion supplementedwith 20% glycerol andﬂash frozen in liquid nitrogen.
Diffraction data from one genistein soaked crystal was collected at
the Advanced Photon Source beamline 19-ID, diffracting to 2.0 Å
resolution. Integration, scaling and merging of the diffraction data
were accomplished with the HKL suite of programs [29]. The structure
was solved with the program MOLREP [30] using the HCN2I-cAMP
crystal structure as the starting model (PDB: 1Q43), water and ligand
excluded. Reﬁnement was carried out using REFMAC [31] and a
composite omit-map generated using CNS [32] was used for modeling
protein and cAMP. Two molecules of cAMP were modeled in the
asymmetric unit and subsequently reﬁned with REFMAC. Rwork and
Rfree of the cAMP-included model were 25.8% and 27.4%, respectively.
This model was used calculate a difference Fourier map (Fo−Fc) and
the resulting map was used to search for positive peaks indicative ofgenistein. Solvent building was subsequently accomplished using
ARP-wARP [33]. The resulting model (Rwork=21.6%, Rfree=24.7%)
and Fo−Fc map were further analyzed for evidence of positive peaks.
Model building and interpretation of maps were carried out in the
programs O [34] and COOT [35].
Allosteric model
The open probability of a channel described by the simple cyclic
MWC model (Fig. 7) is given by Eq. (3) while the V1/2 for voltage-
dependent activation is given by Eq. (4).
Po = 1 + αð Þ= 1 + αð Þ + Lo 1 + αcð ÞT exp zFV =RTð Þ
h i
ð3Þ
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Here V is the transmembrane voltage, α=[cAMP]/Ko, c=Ko/
Kc, Ko and Kc are the dissociation constants for cAMP binding to the
open and closed states respectively, Lo is the opening equilibrium
constant (C/O) in the absence of an applied ﬁeld and z the gating
charge associated with the L(v) equilibrium (assumed to be 2.9 and
4.3 for HCN1 and HCN2, respectively, based on slope values from ﬁts
of the Boltzmann function to steady-state activation curves — see
above). Ko and Kc for HCN2 were set to 15 and 1200 nM based on
the estimates from Wang et al. [5]. Kc for HCN1 was adjusted to
40 nM to reﬂect the weaker coupling of ligand to channel opening.
Ko and Kc for RE channels were set to 1000× higher values. Lo was
set so that the model V1/2 determined by Eq. (4) was equal to the
observed V1/2 of RE channels. [cAMP] was then adjusted to 210 nM
so that the model V1/2 of HCN2 was equal to the observed V1/2. The
effect of genistein was introduced by a 3.1-fold decrease in Lo
combined with loss of cAMP coupling (Kc⁎=Ko) and determined by
solution of Eq. (4).
Chemicals and reagents
Genistein was obtained from Alexis Corporation (Carlsbad, CA)
and cAMP was obtained from Sigma. Stock solutions of these
reagents were prepared in DMSO and H2O, respectively. However,
when cAMP was used at 50 mM, the reagent was dissolved directly
into the recording solution during its preparation. Drug stock
solutions were frozen in aliquots and stored at −20 °C. All other
reagents used in electrophysiology were obtained from Sigma and
were of the highest available purity. The ﬁnal DMSO concentration
was adjusted to be 0.045% (V/V) in both drug and DMSO control
recordings.
Data and statistical analysis
Data analysis was performed in PulseFit (HEKA Elektronik) or
using custom analysis routines written in IgorPro (Wavemetrics
Corporation, Lake Oswego, OR). SigmaStat V3.1 was used to perform
statistical analysis (Systat Software, Point Richmond, CA). A T-test
was used to determine if differences between populations are
signiﬁcant. A paired T-test was used to determine if differences
before and after treatment are signiﬁcant. All data are presented as
mean±SEM.
Results
Genistein modiﬁes activation gating of HCN1 and HCN2
Fig. 1 shows TEVC recordings obtained from Xenopus oocytes
expressing HCN1 (Fig. 1A) or HCN2 (Fig. 1B). In each case current
families obtained in response to hyperpolarizing voltage steps (left)
Fig. 1. Genistein hyperpolarizes activation gating of strongly cAMP-responsive HCN2 channels but modestly depolarizes gating of the weakly cAMP-responsive HCN1 channels. (A, C)
Current records (left) and expanded view of the tail currents (right) before (top) and after (bottom) exposure to 90 μM genistein (HCN1, 30 min; HCN2, 15 min). (B, D) Current–
voltage and steady-state activation curves for the cells shown in A and C respectively. Fits of the Boltzmann function are superimposed on the activation curves.
1942 A.O. Rozario et al. / Biochimica et Biophysica Acta 1788 (2009) 1939–1949and tail currents (right) were obtained before (top) and after
(bottom) exposure of the cells to 90 μM genistein. In close accord
with a previous study [22], we observe that genistein appears toFig. 2. Both HCN1 and HCN2 are robustly facilitated by genisteinwhen they are rendered inse
the CNBD. (A, C) Current records (left) and expanded view of the tail currents (right) before (
steady-state activation curves for the cells shown in A and C respectively. Fits of the Boltzmhave several effects on the channels. 1. The drug elicits a modest
decrease in both the inward and outward current carried by both
HCN1 and 2 (note the change in the scale bars in Fig. 1A, C). 2. Thensitive to physiological concentrations of cAMP throughmutation of a critical arginine in
top) and after (bottom) 30min exposure to 90 μMgenistein. (B, D) Current–voltage and
ann function are superimposed on the activation curves.
1943A.O. Rozario et al. / Biochimica et Biophysica Acta 1788 (2009) 1939–1949kinetics of gating are altered, an effect that is most obviously
revealed by the change in the deactivation of HCN channels where a
general slowing and a perturbation in the shape of the plateau
phase are apparent. 3. Genistein inhibits the voltage-dependent
opening of HCN2 such that more hyperpolarized potentials are
required to open the channels (note that there is no detectable
activation at −65 mV in the presence of the drug whereas there
was signiﬁcant activation at this voltage in the absence of drug) but
the presence of the drug only weakly alters voltage-dependent
opening of HCN1.
To quantify the effect of genistein on the steady-state properties,
we constructed current–voltage (IV) plots (Fig. 1B, D upper panels)
and normalized steady-state activation curves (Fig. 1B, D lower
panels). Inspection of the IV relationships conﬁrms that genistein
decreased the maximal current of both channels (IMAX/IMAX INITIAL for
HCN1 and HCN2 was 0.69±0.04, n=9 and 0.71±0.02, n=11,
respectively). Similarly, inspection of the steady-state activation
curves reveals that opening of HCN2 was indeed shifted hyperpolar-
ized by genisteinwhile the drug weakly depolarized opening of HCN1.
Mean changes in V1/2 of−4.8 mV±1.0 for HCN2 and +2.2 mV±0.6
for HCN1 were both statistically signiﬁcant (Pb0.005; see also Fig. 3).Fig. 3. Genistein locks the voltage dependence of HCN channel opening to an isoform-speciﬁc se
complete current–voltage families were collected. ΔV1/2 APP protocol was executed every 60 s a
records before and after application of genistein obtained from a cell expressing HCN2-R591E.
enhancement at VINT. Note that the capacity transients in the current records have been blanked
determined at 0 mV. The duration and voltage of VINT and VMAX were optimized for each clone.
HCN2-R591E)whileVMAXwas set to−115mV for 2 s (HCN1 andHCN1-R538E) and−125mV a
or DMSO as appropriate. (B) Plots of mean values of the ΔV1/2 APP for HCN1 and HCN1-R538E (
Symbols are as deﬁned in panel C and as used in Figs. 1 and 2. For each condition, data are me
determined from full activation curves in the absence (open)andpresence (ﬁlled) of 90 μMgeni
R538E andHCN2withHCN2-R591E in the presence of 90 μMgenistein. For each condition, data
treated groups were signiﬁcant in all cases (Pb0.005).Genistein modiﬁcation of HCN channel gating is altered by mutation of a
conserved arginine in the CNBD
A notable difference between HCN1 and HCN2 lies in the strength
of coupling between cAMP binding and channel opening. Thus, cAMP
strongly facilitates opening of HCN2 but has only relatively modest
effects on HCN1. In light of the observation that HCN2 was more
responsive to genistein, we asked if channel regulation by the
isoﬂavonoid was dependent upon the activation status of the gating
ring. To address this questionwe recorded from cells expressing either
HCN1-R538E or HCN2-R591E.
Fig. 2 shows representative TEVC recordings obtained from cells
expressing either HCN1-R538E (Fig.1A, B) or HCN2-R591E (Fig.1C, D).
Qualitatively, the gating of these two constructs appears to be
indistinguishable from their wild type counterparts (compare records
to those in Fig.1). However, quantitatively, it is clear that under control
conditions the mutant channels activate somewhat hyperpolarized
relative to the cognate wild type channels. This shift is most apparent
in the more cAMP-responsive HCN2 background. Thus, inspection of
the current records shows that there is marked activation of HCN2
below ∼−60 mV (Fig. 1C) while HCN2-R591E does not activate untiltpoint. (A) Schematic representation of the experimental paradigm. IV indicateswhen the
s shown by lower time ticks. Shown below is a representative voltage record and current
Current records in the absence and presence of 90 μM genistein are scaled to IMAX to show
for clarity. In all such experiments, the holding potential was−30mV and the tails were
VINT was generally set to the V1/2 and was 3 s (HCN1 and HCN1-R538E) or 10 s (HCN2 and
nd 5 s (HCN2 andHCN2-R591E). Black bar indicates time of perfusionwith 90 μMgenistein
top) or HCN2 and HCN2-R591E (bottom) in the absence and presence of 90 μM genistein.
an±SEM of 5 to 19 individual recordings. (C) V1/2 of activation (bottom) and ΔV1/2 (top)
stein. Thebluedashed lines show the correspondenceof theﬁnalV1/2 forHCN1withHCN1-
aremean±SEMof 6 to 14 individual recordings. Differences between control and genistein
1944 A.O. Rozario et al. / Biochimica et Biophysica Acta 1788 (2009) 1939–1949the voltage is stepped below ∼−80 mV (Fig. 2C). The hyperpolarizing
shift in gating observed in intact Xenopus oocytes upon mutation
of the arginine to a glutamate (V1/2 of HCN1 and HCN1-R538E is
−65.7 mV±0.3, n=113 versus −75.0 mV±0.3 n=212 while V1/2
of HCN2 and HCN2-R591E is −77.4 mV±0.4, n=131 versus
−93.0mV±0.6 n=74) is considered to represent the loss of coupling
of HCN-RE channels to basal levels of cAMP [5,18].
What is the action of genistein on the cAMP-unresponsive HCN-RE
channels? Inspection of the current records in Fig. 2 reveals that
exposure to genistein results in a similar change in gating kinetics
with a slowing of deactivation and a decrease in IMAX as seenwhen the
drug is applied to wild type channels (Fig. 1; IMAX/ IMAX INITIAL for
HCN1-R538E and HCN2-R591E was 0.58±0.04, n=8 and 0.75±0.05,
n=9, respectively). Surprisingly, the action of genistein on the
voltage-dependent opening of both HCN1 and HCN2 channels is
dramatically altered by the introduction of the RE mutations.
Thus, inspection of the current records shows that HCN1-R538E
channels open at a markedly more depolarized potential in the
presence, as compared to the absence, of genistein. This apparent
facilitation of channel gating is clearly revealed by the right shift in the
steady-state activation curve (Fig. 2B). Even more dramatically, the
opening of HCN2-R591E channels is not inhibited by genistein (as
observed for HCN2), but, rather, is robustly facilitated by the drug
(Fig. 2C, D). Mean changes in V1/2 of +9.8 mV±0.9 for HCN1-R538E
and +13.2 mV±2.1 for HCN2-R591E were both statistically sig-
niﬁcant (Pb0.001; see also Fig. 3).Fig. 4. The action of genistein on the voltage dependence of HCN2 is determined by the activa
experimental paradigm (upper). IV indicates when the complete current–voltage relationship
Voltage paradigm used to determine ΔV1/2 APP (lower). (B) Representative records obtained
records) or presence of a saturating concentration (lower records) of cAMP. In each family, re
followingwashout of the isoﬂavonoid (blue). Records are scaled tomaximal current evoked a
cAMP and the current inhibition at this voltagewhen the CNBD is fully occupiedwith cAMP (s
for the patches shown in B.We were concerned that the extended time required to obtain
complete activation curves before and after application of genistein
may have occluded an accurate assessment of the effects of the
drugs by convolving it with an unanticipated rundown of gating
during prolonged recordings. To circumvent this possibility, we
employed a simple two-step protocol that allowed us to follow
changes in the V1/2 of channel activation with a high temporal
ﬁdelity during drug onset (see Fig. 3A and Materials and methods).
Fig. 3B shows plots of the derived parameter ΔV1/2 APP for HCN1 and
HCN1-R538E (upper panel) and HCN2 and HCN2-R591E (lower
panel) exposed to either 90 μM genistein or DMSO vehicle control
normalized to the control value of the initial V1/2 determined from
full steady-state activation curves for each channel. These data
conﬁrm that introduction of the RE mutation results in an enhanced
facilitation of HCN1 and the inversion of the response of HCN2 from
inhibition to facilitation in response to genistein in accord with the
data shown in Figs. 1 and 2.
We considered three possible hypotheses to account for the ability
of these “cAMP-uncoupling” mutations to alter channel responses to
genistein: 1. Mutation of the critical arginine to a glutamate altered
the channel architecture and gating in a previously undescribed
manner; 2. Genistein can act as an RE sensitive partial agonist at the
cAMP site and 3. cAMP occupancy and/or the activation status of the
CNBD inﬂuences the channel response to genistein interacting
elsewhere. The data presented in the following sections suggest that
the latter hypothesis is correct.tion status of the cyclic nucleotide gating apparatus. (A) Schematic representation of the
was collected.ΔV1/2 APP protocol was executed every 30 s as shown by lower time ticks.
from two inside-out patches containing HCN2 channels recorded in the absence (upper
cords were obtained in the absence (gray) and presence (black) of 90 μM genistein and
t VMAX to show the drug dependent enhancement of the current at VINT in the absence of
ee arrows). (C) Plots ofΔV1/2 APP for patches shown in B. (D) Plot of themaximal current
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occupancy of the CNBD and independent of the presence of the arginine
to glutamate mutation
Inspection of the endpoint for the shift in activation gating
reported by either ΔV1/2 APP (Fig. 3B) or the fully determined V1/2
(Fig. 3C) shows that the mid-point of activation of each channel pair
(HCN1 versus HCN1-R538E and HCN2 versus HCN2-R591E) con-
verges. One interpretation of this could be that this is coincidental
with the altered basal energetics of wild type and mutant channels
offset by corresponding changes in the coupling energy of genistein. A
simpler, and therefore more attractive, interpretation of these data is
that genistein uncouples the channels from the gating ring such that
both the ring's inhibitory effect, and the cAMP-mediated relief thereof,
are lost. In such a scenario, wild type channels (which start out gating
in a cAMP-modiﬁed state wherein inhibition by the gating ring is
relieved) and RE channels (which start out gating in a cAMP-unbound
state wherein inhibition by the gating ring is intact) end up gating in a
genistein modiﬁed state independent of where they started with
respect to the basal inhibition by the gating ring or its relief by cAMP.
To further investigate whether cAMP occupancy of the CNBD
inﬂuences the response of HCN channels to genistein, we recorded
HCN2 and HCN2-R591E channels in excised inside-out patches where
we could control the presence or absence of cAMP as well as genistein.
Upon patch excision, HCN gating shifts hyperpolarized by 30–40 mV
due, at least in part, to loss of coupling to basal cAMP but also as a
consequence of loss of coupling to intracellular factors including acidic
lipids [28,36–38]. Although this shift is largely completed in the ﬁrstFig. 5. The cAMP dependence of genistein modulation is recapitulated in the CNBD-disable
obtained from inside-out patches containing HCN2-R591E channels in the absence (upper rec
to theΔV1/2 APP paradigm (top). In each family, records were obtained in the absence (gray) a
Records are scaled to maximal current evoked at VMAX to show the drug dependent enhanc
voltage when the CNBD is occupied with cAMP (see arrows). (B) Mean ΔV1/2 APP for HCN2 a
condition, data are mean±SEM of 5 to 12 individual recordings. For each clone the effect of g
effect in the absence of cAMP (Pb0.002). The overall genistein dependent shift in gating for e
the maximal current in response to genistein in the absence or presence of cAMP. Symbols3 min following excision, a slow drift in gating can obscure drug-
mediated changes in gating if activation is determined with time
intervals that are too far apart. To circumvent this problem, we again
utilized the two-step determination of the parameterΔV1/2 APP. Fig. 4A
shows the general protocol and the voltage paradigm used in these
recordings. Fig. 4B shows the superimposed current records obtained
before, during and after perfusion of patches containing HCN2
channels with 90 μM genistein. One patch was recorded in the
presence of cAMP (Fig. 4B lower panel) and the other in the absence of
the nucleotide (Fig. 4B upper panel). In each case the superimposed
sweeps have been normalized to the maximum current response to
show how channel opening at the intermediate voltage was altered by
genistein after compensating for suppression of the maximal current.
It is apparent that in the presence of a saturating concentration of
cAMP the current through HCN2 at the intermediate voltage is
suppressed by genistein. This ﬁnding is analogous to the action of
genistein on HCN2 in intact oocytes where the basal cAMP level is high
enough to facilitate the channels. However, when we determined the
effect of genistein in the absence of cAMP, gating of wild type HCN2
was facilitated — the current at the intermediate voltage is enhanced
relative to control and washout. Plots of the parameter ΔV1/2 APP
obtained from these two recordings reveals the reversible facilitation
of gating in the absence of cAMP and inhibition of gating in the
presence of cAMP. Consistent with the results obtained in TEVC (Figs.1
and 2), genistein suppressed the maximum current in both the
presence and absence of cAMP in IOPC (Fig. 4D).
Previous studies in both HCN and CNG channels have shown that
mutation of the critical arginine to glutamate does not prevent cAMPd channel HCN2-R591E when cAMP is elevated to 50 mM. (A) Representative records
ords) or presence of a high concentration (lower records) of cAMP obtained in response
nd presence (black) of 90 μMgenistein and followingwashout of the isoﬂavonoid (blue).
ement of the current at VINT in the absence of cAMP and the current inhibition at this
nd HCN2-R591E in response to genistein in the absence or presence of cAMP. For each
enistein on ΔV1/2 APP in the presence of cAMPwas signiﬁcantly different from the drug's
ach channel is shown next to the respective values of ΔV1/2 APP. (C) Mean suppression of
as in B.
1946 A.O. Rozario et al. / Biochimica et Biophysica Acta 1788 (2009) 1939–1949from binding to or activating the CNBD, it simply shifts the apparent
afﬁnity for cAMP into the high mM range [6,18,20]. Accordingly, we
predicted that the mutant HCN2-R591E channel should behave
similarly to HCN2 if cAMP were to be driven into its disabled CNBD.
In accord with this prediction, in the presence of 50 mM cAMP, gating
of HCN2-R591E was inhibited by genistein (Fig. 5A lower records)
while channel gating was enhanced if the isoﬂavonoid was applied in
the absence of cAMP (Fig. 5A upper records). The response of HCN2-
R591E to genistein in the presence of 10 μM cAMP (a concentration
that inverted the behavior of HCN2 to genistein but which is too low to
elicit signiﬁcant binding to the RE CNBD) was indistinguishable from
the action of genistein in the absence of cAMP (data not shown). Thus,
the response of HCN2-R591E to genistein is qualitatively indistin-
guishable from that of wild type HCN2.
Fig. 5B presents a summary of the effects of genistein on the mid-
point of activation gating of HCN2 and HCN2-R591E channels
recorded in IOPC. As suggested from the representative data shown
in Figs. 4 and 5A, the qualitative responses of wild type and HCN2-
R591E channels to the convergent effects of genistein and cAMP are
identical. Moreover, while there is a small discrepancy in the
amplitudes of the genistein-mediated shifts in gating in the two
constructs, the overall net effect of genistein on channel gating
(comparing between cAMP-bound and unbound states) is similar (∼7
to 10 mV). Furthermore, this effect of genistein is close to the total
genistein-mediated difference calculated for cAMP-bound (HCN2)
and cAMP-unbound (HCN2-R591E) channels in intact cells (∼15–
18 mV, See Fig. 3B, C) supporting the notion that the effects of
genistein onwild type versus HCN-RE channels in intact oocytes arises
from the difference in the cAMP occupancy and activation of the
CNBD. These ﬁndings argue against genistein acting as a detector of
a heretofore unobserved effect of the RE mutation on HCN channel
basal gating and against genistein acting as an RE sensitive cAMP site
partial agonist.Fig. 6. Genistein modulation of HCN channel gating does not require the presence of
the CNBD. (A) Schematic representation of an HCN ion channel subunit. White boxes:
S1–S6 transmembrane helices. Grey box: pore helix. GYG: selectivity ﬁlter. Blue and red
elements in the C-terminus: C-linker and CNBD wherein lines represent β-strands/
disordered sequences and boxes represent helices [7]. Red R: critical arginine (R538 and
R591 in HCN1 and 2 respectively) that forms an ionic bond with the cyclized phosphate
of the cAMP. Green dashed lines: sites of truncation (HCN2-ΔCNBD, V526stop; HCN1-
ΔCNBD, V473stop; HCN1-ΔCterm, S391stop). Cartoon is scaled so that the linear
distance of each segment is approximately proportional to the number of residues in
that element. (B) Mean ΔV1/2 APP for HCN2-ΔCNBD (top), HCN1-ΔCNBD (middle) and
HCN1-ΔCterm (bottom) in response to 90 μM genistein (ﬁlled symbols) or DMSO
vehicle (open symbols). For each condition, data are mean±SEM of 8 to 20 individual
recordings. Differences between control and genistein treated groups were signiﬁcant
for both ΔCNBD constructs (P values of b0.001) but not for HCN1-ΔCterm.Genistein allosterically modiﬁes HCN gating in a manner dependent on
the presence of an intact C-terminus
How can genistein enhance activation of HCN channel gating in the
absence of cAMP but have little effect (on the gating of the weakly
cAMP-responsive HCN1 channels) or an inhibitory effect (on the
strongly cAMP-responsive HCN2 channels) in the presence of cAMP?
We can consider two simple hypotheses to account for this behavior:
1. Genistein acts as a competitive partial agonist at the cAMP binding
site but its binding is insensitive to the presence of a positive or
negative charge on the amino acid that is important in docking cAMP.
2. Genistein acts as an allosteric modiﬁer that moves the channel
closer to the open state thereby facilitating opening but at the expense
of weakening the coupling energy imparted by cAMP (see Discussion
for more details). We addressed this question in two ways. First, we
asked whether genistein could occupy the HCN2 CNBD. To do this we
soaked crystals of the gating ring in genistein and determined the
structure by X-ray crystallography (see Materials and methods for
details). We observed no density due to genistein indicating that the
molecule was not stably located in the structure (see Supplementary
data for the structure factor ﬁle, crystallographic and reﬁnement
statistics and the resultant pdb ﬁle) be it in the cAMP pocket or
elsewhere. Second, we asked if deletion of the CNBD would eliminate
the action of genistein as predicted if it is a partial agonist acting
within the CNBD. Fig. 6 shows that genistein facilitated activation of
both HCN1-ΔCNBD and HCN2-ΔCNBD. These ﬁndings indicate that
genistein neither acts as a competitive partial agonist nor does it
modify behavior of HCN channels by binding to a discrete site in the
gating ring itself. Intriguingly, deletion of the C-linker (which acts not
only as the tetramerization interface within the gating ring but also
the structural interface between the gating ring and the membrane
embedded pore and voltage-sensing module) appears to largely,
but not completely, abolish the sensitivity of HCN1 to genistein (in
the lowest panel of Fig. 6B the application of genistein, but not
vehicle, resulted in a small, albeit statistically insigniﬁcant, deviation
in ΔV1/2 APP). HCN2-ΔCterm does not form functional channels
precluding analysis of this construct.
Discussion
The mechanism by which cAMP binding to the C-terminal gating
ring enhances activation of HCN channels has been investigated using
a number of approaches, but functional evidence for some aspects of
the resultant gating models [2,5,6,9,14,18] as well as of the
physiological function of cAMP binding in vivo [19] has depended
on utilization of cAMP-insensitive channels generated by mutation of
an arginine that is critically involved in initial binding of the
nucleotide [2,7,18,20]. Here we investigated an unusual phenotype
of these HCN-RE channels that suggested their gating might not well
reﬂect the cAMP-independent gating of wild type HCN subunits.
Speciﬁcally, we studied the response of wild type and HCN-RE
channels to the estrogenic isoﬂavonoid tyrosine kinase inhibitor,
genistein. Our ﬁndings reveal that the divergent responses of HCN and
HCN-RE channels actually arise as a direct result of the uncoupling of
the CNBD from cAMP and provide support for the hypothesis that the
gating mechanism of the cAMP-disabled HCN channels faithfully
reﬂects the cAMP-independent activation of wild type HCN channels.
Our results suggest that this action of genistein is exerted through an
allosteric uncoupling of the CNBD from channel opening rather than
the drug acting as a partial agonist at the CNBD. Below, we consider
these ideas in more detail and consider the speciﬁc and general
implications of our ﬁndings with regard to HCN channel regulation
and the use of mutants in helping unravel pathways of regulation.
To provide a framework within which to consider how genistein
may give rise to the different responses in HCN and HCN-RE channels,
we consider a simple cyclic allosteric model (Fig. 7A). In this model,
Fig. 7. Genistein acts on HCN channel gating to synchronously alter the ease of opening and the efﬁcacy of cAMP coupling. (A, B) Schematic representation of an allosteric model for
HCN activation in the absence (A) or presence (B) of genistein. The corners of each quadrant each represent a pair of channel subunits (shown as black legs with associated CNBDs at
the bottom). The closed channel (left hand pairs) is stabilized relative to the open channel (right hand pairs) by bonds (horizontal lines between subunits). cAMP (orange triangle)
can bind to the CNBD in the open or closed state but the binding is enhanced by channel activation (CNBD forms closer associations with cAMP) yielding the coupling energy. The
action of genistein is modeled as moving the channel closer to the open state such that the bonds stabilizing the closed state are weakened (horizontal lines are dashed) with the
closed state CNBD also adopting a conformation closer to the open state (closer association with cAMP), which weakens the coupling energy available on channel opening. Voltage-
dependent channel opening is represented by the horizontal transitionswhere L(v) and L⁎(v) represent the control and genisteinmodiﬁed voltage-dependent equilibrium constants.
Binding of cAMP is represented by the vertical transitions with the dissociation constants for binding to the open and closed states represented by Ko, Kc and Kc⁎ (genistein modiﬁed
Kc). The coupling energy factor, c is equal to Ko/Kc and Ko/Kc⁎ in the absence and presence of genistein respectively. (C) Values of basal (left) and genistein modiﬁed (right) model
parameters and simulated values of the V1/2 and ΔV1/2 for channels under TEVC with a concentration of endogenous cAMP ﬁxed at 210 nM (see Materials and methods for details).
Values of the V1/2 reported in columns Lo/3.1 and c⁎=1 report the V1/2 that would be observed if only that parameter was changed by genistein while the V1/2 shown in column
ΔLoΔc is that observed when drug alters both parameters. ΔV1/2 is the net effect on gating predicted to occur upon introduction of genistein.
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genistein (indicated by lines between the subunits). Activation of the
channel involves a concerted change that includes opening of the pore
and conversion of the CNBD from a low afﬁnity site to a site with high
afﬁnity for cAMP. The tighter binding of cAMP to the activated CNBD
(KobKc) imparts energy to stabilize the open state as shown by the
enhancement of the voltage-dependent opening equilibrium, L(v), by
the factor c, which is equal to Ko/Kc. Within this framework, we can
interpret the action of genistein (Fig. 7B) as eliciting a weakening of
the closed state such that the channel moves closer to the open state
(hence its ability to facilitate the channels in the absence of cAMP).
However, a cost of this would be to also move the CNBD closer to the
open state, thereby reducing the difference between Ko and Kc and,
hence, weakening the coupling energy that cAMP can impart to
enhance channel opening. As shown in Fig. 7C, amodest adjustment of
Lo (3.1-fold decrease) combined with collapse of the Ko/Kc ratio is
adequate to generate changes in the overall V1/2 that mirror the
results we observe upon exposure of HCN channels to genistein. Thus,
the model can describe the depolarization of both HCN1 and HCN1-
R538E (ΔV1/2=+2mV and +10 mV as observed in the presence of a
physiological concentration of cAMP in TEVC). Similarly, the same
genistein-mediated changes in Lo and Ko/Kc would yield a
depolarization of HCN2-R591E (ΔV1/2=+7 mV) but a hyperpolariz-
ing shift in the gating of HCN2 (ΔV1/2=−8 mV). It should be noted
that while aspects of the model are set according to observed data the
adjustments to simulate the effects of genistein were arbitrarily
chosen and do not necessarily represent a unique solution. Moreover,it is important to note that the signiﬁcance of the model is that,
despite its simplicity (in that it does not separate activation and
opening [10,13], account for the presence of multiple voltage sensors
[39–42] or incorporate either a modal shift in the behavior of the
sensors [41,43,44] or the presence of inactivated states [10]), it does,
nonetheless, show how the observed divergent responses of HCN and
HCN-RE channels to genistein do not require that the channels have
fundamentally different gating.
What are the decrease in IMAX and the changes in gating kinetics
upon exposure to genistein? The effect of genistein on channel
kinetics will likely have at least two components. Thus, the
observable rates of activation and deactivation will change in concert
with the shift in the V1/2 irrespective of whether the drug is acting
to alter the voltage-sensing reactions or the opening transitions
but these effects may be convolved with a slowing of gating that
occurs independently of a shift in the V1/2 as a result of altered
phosphorylation/coupling of a kinase to the C-linker (see below).
Similarly, the decrease in IMAX could arise in a number of ways
including a decrease in POPEN (if the drug alters the opening reaction
directly or binds preferentially to closed but not open states [45]) or
a simple block of the channel. As our primary goal here was to
determine the basis of the divergent effects of genistein on voltage
gating of HCN and HCN-RE channels and changes in both IMAX and
kinetics can have other confounding origins, we have not considered
these other factors further.
Why does genistein only weakly facilitate (HCN1) or inhibit
(HCN2) opening of full-length HCN channels in the presence of a
1948 A.O. Rozario et al. / Biochimica et Biophysica Acta 1788 (2009) 1939–1949physiological concentration of cAMP but facilitate gating of HCN
channels devoid of the CNBD when each of these interventions are
able to relieve the CNBD-mediated contribution to closed state
stability [3]? In wild type channels, the net inhibitory effect of
genistein presumably reﬂects a balance between an enhancement of
the ease of channel opening and the loss of the coupling energy of
bound nucleotide. However, in the background of HCN-ΔCNBD
channels, there is no coupling energy to give up so the response to
drug will be dominated by the remaining component — the
enhancement of opening.
Where does genistein interact with the channels to elicit the
change in opening and cAMP coupling? In light of the observations
that genistein does not bind within the C-linker per se but deletion of
this motif greatly weakens the drug's functional effect on the channel,
it is tempting to speculate that the isoﬂavonoid is associating at the
interface of the C-linker and membrane and/or membrane embedded
pore and voltage-sensing elements of the channel. However, in the
absence of deﬁnitive evidence for binding to such a site we have no
way to exclude the possibility that the loss of the C-terminus weakens
the drug's actions by modifying a site elsewhere in the protein.
In several recent reports the effects of genistein and PP2 on HCN
channel gating have been used to support the idea that HCN channels
are regulated by tyrosine phosphorylation. An apparent ineffective-
ness of daidzein and PP3 (tyrosine kinase inactive analogues of
genistein and PP2, respectively) was used to strengthen this
hypothesis [21–23]. However, others have reported, as we show
here, that genistein can have non-catalytic effects on HCN channels
[24,25] — though such a ﬁnding alone does not preclude the
possibility that such drugs alter HCN channels via channel association
with a genistein:tyrosine kinase complex as has been suggested for
CNG channels [46–49]. Moreover, as previously reported by others
[21,22], we ﬁnd that daidzein is relatively ineffective against cAMP-
bound HCN channels (data not shown). However, we ﬁnd that
daidzein can mimic the effects of genistein when HCN channels are
cAMP-unbound (albeit generally more slowly and often with a
reduced efﬁcacy — data not shown). Such effects of daidzein can be
readily explained within the context of our model but are hard to
reconcile with the hypotheses that the effects of genistein (andmaybe
PP2) are due solely to inhibition of catalytic effects of tyrosine kinases
or an allosteric effect of interaction of the channels with a drug:kinase
complex. A second line of evidence used to support a role for tyrosine
phosphorylation of HCN (and CNG) channels is to probe the effect of
site-directed elimination of select tyrosine residues [21,46,50–52].
While this is a valid and important line of investigation, our ﬁndings
suggest that loss of sensitivity to drugs upon mutation of these
residues (which all fall within the gating ring andmay, therefore, alter
cAMP coupling) may have a very different origin than elimination of
kinase substrate site. This is not to say that tyrosine kinases do not also
exert effects on HCN (or CNG) channels. For example, this hypothesis
has received support from studies using over expression of, and
interaction with, kinases, phosphatases and dominant negative
constructs thereof [21,50,53]. Our ﬁndings simply serve notice that
the complex energetic inputs to gating can confound interpretation of
even the simplest experiment and this needs to be taken into account.
In summary, our results suggest that estrogenic type compounds
such as genistein and, perhaps, also endogenous steroidal compounds,
can act as allostericmodiﬁers of HCN channel function in amanner such
that the phenotype is determined by the activation status of the cyclic
nucleotide gating ring. This idea is in keepingwith the ﬁnding that HCN
channels are functionally regulated by association with lipid rafts [54]
and bears an appealing similarity to the manner in which cortisone
alters the function of a Kv1–Kvβ complex [55]. Importantly, we show
that the divergent responses of wild type and cAMP-disabled HCN
channels to isoﬂavonoids do not reﬂect an underlying disruption of
channel activation or opening in the mutants, rather these phenotypes
directly emerge from the designed loss of coupling to cAMP.Acknowledgments
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